Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: A report from the I-CML-Ped Study

Chronic myeloid leukaemia (CML) is a rare disease in children. The frequency and outcome of children evolving to accelerated phase (AP) or blastic phase (BP) under treatment with imatinib is unknown. The aim of the current study is to assess the incidence of progression from CML in chronic phase with imatinib frontline in a paediatric setting and describe the management and outcome of these patients.

Source: European Journal of Cancer - August 12, 2020 Category: Cancer & Oncology Authors: Deborah Meyran, Arnaud Petit, Joelle Guilhot, Meinolf Suttorp, Petr Sedlacek, Eveline De Bont, Chi Kong Li, Krzysztof Kalwak, Birgitte Lausen, Srdjana Culic, Barbara de Moerloose, Andrea Biondi, Fr édéric Millot Tags: Original Research Source Type: research